<DOC>
	<DOCNO>NCT00977431</DOCNO>
	<brief_summary>This study phase I , open label trial determine Maximum Tolerated Dose ( MTD ) , safety , pharmacokinetics , efficacy BIBW 2992 ( epidermal growth factor receptor ( EGFR ) inhibitor ) use combination : - radiotherapy alone ( patient unmethylated ( function ) MGMT gene regulator ) - radiotherapy Temozolomide ( patient methylated ( silence ) MGMT gene ) treat newly diagnose patient Grade IV Glioblastoma ( primary brain cancer ) .</brief_summary>
	<brief_title>Open Label Trial Explore Safety Combining Afatinib ( BIBW 2992 ) Radiotherapy With Without Temozolomide Newly Diagnosed Glioblastoma Multiform</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologicallyconfirmed WHO Grade IV newly diagnose malignant glioma . 2 . Proven MGMT gene promoter methylation status 3 . Available early postoperative Gdenhanced MRI ( within 72 hour initial surgery ) . In case patient perform Gdenhanced MRI within 72 hour post surgery , GdMRI perform prior start study treatment . 4 . Age equal 18 year less 70 year entry 5 . KPS equal 70 % 6 . Patients receive corticosteroid receive stable decrease dose least 14 day start treatment . 7 . Written inform consent consistent local law ICHGCP guideline . Exclusion criterion : 1 . Less two week surgical resection major surgical procedure start treatment . 2 . Planned surgery diseases 3 . Placement GliadelÂ® wafer surgery . 4 . Prior plan radiotherapy cranium include brachytherapy and/or radiosurgery GBM . 5 . Treatment investigational drug ; participation another clinical study include exposure investigational product within past 4 week start therapy concomitantly study . 6 . Active infectious disease require intravenous therapy . 7 . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. 8 . Gastrointestinal disorder may interfere absorption study drug chronic diarrhoea . 9 . Patients know preexist interstitial lung disease 10 . Serious illness concomitant nononcological disease consider investigator incompatible protocol . 11 . Patient le 3 year free another primary malignancy except : primary malignancy either currently clinically significant require active intervention ( basal cell skin cancer cervical carcinoma situ ) . Existence malignant disease allow . 12 . Cardiac leave ventricular function rest ejection fraction le 50 % . 13 . Absolute neutrophil count ( ANC ) less 1500/mm3 . 14 . Platelet count less 100,000/mm3 . 15 . Bilirubin great 1.5 x upper limit institutional norm . 16 . Aspartate amino transferase ( AST ) great 3 x upper limit institutional norm . 17 . Serum creatinine great 1.5 x upper limit institutional norm . 18 . Patients sexually active unwilling use medically acceptable method contraception . 19 . Pregnancy breastfeed . 20 . Patients unable comply protocol . 21 . Known suspected active drug alcohol abuse . 22 . Known hypersensitivity BIBW 2992 excipients trial drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>